CABA
NASDAQ
$2.75
Cabaletta Bio Inc (CABA)
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of T-cell therapies designed for patients with B-cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $13.38 (+386.55%)
Market Cap
$463M
FCF 5Y CAGR
+35.81%
Free Cash Flow Yield
-30.94%
Beta (5Y)
1.66
Price Chart
Valuation
Market Cap$463M
P/B4.20
Profitability
EBITDA-$178M
EPS-$1.38
Financial Health
Free Cash Flow Yield-30.94%
Growth & Risk
EPS 5Y CAGR+8.20%
FCF 5Y CAGR+35.81%
Beta (5Y)1.66
Sharpe Ratio0.92